Core Insights - The article discusses the effectiveness of oral semaglutide in managing type 2 diabetes and supporting weight loss, providing more options for weight loss medications [8][10][12]. Study Results - Participants taking oral semaglutide experienced a significant weight loss of 5.8 kg and a notable reduction in HbA1c levels from 8.6% to 7.3% over the study period [10][11]. - The study involved 187 participants with an average age of 58 years, where 54% were male and 88% were white. The average duration of diabetes was 8.7 years, with an initial average weight of 103.1 kg [10][11]. - At the end of the study, 48% of participants had HbA1c levels below 7%, indicating improved glycemic control [11]. Treatment Satisfaction - A high level of treatment satisfaction was reported, with 26.1% and 55.4% of participants finding semaglutide easy or very easy to take, respectively [11]. - By the end of the study, approximately 79% of participants continued with oral semaglutide treatment, with an average dosage of 10.6 mg [11]. Mechanism of Action - The study highlights the use of a small molecule permeation enhancer, SNAC, which aids in the absorption of semaglutide in the stomach, ensuring it achieves the same glycemic effects as injectable forms [12][14]. Market Implications - The introduction of oral semaglutide is seen as a game-changer, particularly for individuals who prefer oral medications over injections due to needle phobia [14][15]. - The focus is on personalized treatment options based on patient and clinician goals, enhancing the overall treatment experience [15].

Core Viewpoint - The article highlights the escalating global obesity crisis, emphasizing the urgent need for action to address the health challenges posed by obesity, which affects both physical and mental health [6][14]. Group 1: Global Obesity Statistics - As of 2021, 2.11 billion adults and 493 million children and adolescents were affected by overweight or obesity, with projections indicating that by 2050, 60% of adults (approximately 3.8 billion) and 31% of children and adolescents (approximately 750 million) will be affected [6]. - Obesity is linked to various health issues, including cardiovascular diseases, diabetes, and certain cancers, as well as mental health challenges such as depression and anxiety [6]. Group 2: Impact of Obesity on Brain Health - Long-term obesity significantly alters brain structure, functional connectivity, and cognitive levels in adults, with potential reversibility through weight loss [6][9]. - Chronic low-grade inflammation, oxidative stress, and mitochondrial dysfunction caused by obesity can damage the brain through multiple biological pathways [7]. - Research indicates that older obese individuals experience more severe brain volume loss compared to younger obese individuals, highlighting the complex dangers obesity poses to brain health [8]. Group 3: Research Findings on Obesity and Cognition - A study utilizing data from 50,538 participants in the UK Biobank analyzed the longitudinal patterns of obesity and their relationship with brain structure and cognitive function [9]. - Participants were categorized into five groups based on their obesity levels over time, revealing that the group with decreasing obesity showed the least negative impact on brain structure and cognitive function [11]. - The study found that the cognitive performance of the weight-decreasing group was similar to that of the low obesity stable group, suggesting that weight loss may help reverse cognitive damage caused by obesity [12]. Group 4: Clinical Implications - The research underscores the importance of long-term monitoring and management of obesity through multi-faceted approaches, providing a scientific basis for early intervention in obesity-related cognitive decline [14].

Core Viewpoint - The article discusses the successful results of the DREAMS-3 clinical trial for the dual receptor agonist IBI362 (Mastrutide), highlighting its efficacy in reducing HbA1c and body weight in Chinese patients with type 2 diabetes and obesity [6][8]. Group 1: Clinical Trial Results - The DREAMS-3 trial demonstrated that 48.0% of patients in the Mastrutide group achieved HbA1c < 7.0% and a weight loss of ≥10% by week 32, significantly outperforming the Semaglutide group at 21.0% (P < 0.0001) [6]. - The mean change in HbA1c from baseline at week 32 was -2.03% for the Mastrutide group and -1.84% for the Semaglutide group, with both showing statistically significant results (P < 0.05) [6]. - The average percentage weight loss from baseline at week 32 was 10.29% for Mastrutide and 6.00% for Semaglutide, indicating a notable difference in efficacy [6]. Group 2: Study Design and Demographics - The DREAMS-3 trial was a multicenter, randomized, open-label Phase III study involving 349 Chinese participants with early-stage type 2 diabetes and obesity, with an average age of 42.4 years and an average disease duration of 1.8 years [8]. - Participants had a baseline HbA1c of 8.02%, a baseline weight of 90.47 kg, and a baseline BMI of 32.98 kg/m², indicating a population with significant metabolic challenges [8]. - The study randomized participants to receive either 6 mg of Mastrutide or 1 mg of Semaglutide for 32 weeks, followed by an extension phase based on weight loss outcomes [8]. Group 3: Safety Profile - The overall safety profile of Mastrutide was consistent with previous clinical studies, with no new safety signals identified during the trial [6]. - Gastrointestinal adverse events were the most common, primarily mild to moderate in severity, indicating a manageable safety profile for patients [6].

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 现代社会的快节奏生活正在悄然重塑人类的睡眠模式，熬夜与紊乱的作息逐渐成为健康隐患。最新科学研究证实，睡眠问题不仅导致日 间疲惫，更会直接干扰血糖代谢稳态。来自JAMA Ne twor k Ope n的突破性研究《成人睡眠时长、入睡时间与连续血糖监测的变化轨 迹》首次采用动态监测方法，揭示睡眠时长缩短与入睡时间推迟会显著加剧血糖波动，这种影响甚至超过单纯熬夜的危害。该研究为理 解睡眠紊乱与代谢疾病之间的关联提供了全新证据。 这项开创性研究采用连续血糖监测技术，对受试者睡眠模式与血糖水平进行长期追踪。结果显示，持续睡眠不足6小时的人群，其血糖 波动幅度比睡眠充足者高出40%。更令人警惕的是，相比固定时间熬夜，不规律的就寝时间会导致更严重的血糖调节异常。研究团队指 出，人体生物钟与糖代谢存在精密协同，当入睡时间每日差异超过90分钟时，胰岛素敏感性会出现明显下降。这些发现完美解释了为何 轮班工作者和跨时区旅行者更容易出现代谢紊乱。 深入分析数据发现， ...

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 2024年4月6日，《柳叶刀》刊登了一项由四川大学华西医院李舍予教授担任通讯作者的系统综述与网络Meta分析。该研究聚焦于评估7种药 物对超重及肥胖成年人的减重效果和安全性。研究结果显示，在所有药物中，芬特明-托吡酯组合和GLP-1受体激动剂的减重效果最为显著； 而在GLP-1受体激动剂类药物中，司美格鲁肽可能展现出最强的减重潜力。 01 • 研究方法 研究团队系统性检索了PubMed、Embase和Cochrane图书馆（CENTRAL）三大数据库，筛选截至2021年3月23日发表的关于超重及肥胖成年人 使用减重药物的随机对照试验（RCTs）。 排除标准包括：采用交叉设计的研究；联合使用多种药物（如芬特明-托吡酯与安非他酮-纳曲酮联合）；受试者存在心理疾病；孕妇或体重正 常人群；以及非英文发表的论文。 本次Meta分析共纳入七种药物：芬特明-托吡酯、纳曲酮 ...

整理 | GLP1减重宝典内容团队 2025年10月22日，礼来启动了GLP-1/GIP双靶点Brenipatide用于治疗中至重度酒精使用障碍（AUD，即嗜酒症）的两项三期临床试验 RENEW-ALC-1、RENEW-ALC-2。 此次启动的两项三期临床分别将入组1100例患者，预计2028年4月完成。 *本文仅供医疗卫生专业人士参考 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 加入专家库与我们深度讨论 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士获取行业真知灼见的首要选择。加入 专家库请添加下方「运营负责人」微信，并提供名片和必要的个人信息。 Brenipatide是继替尔泊肽后，礼来推出的第二款GLP-1/GIP双靶点药物。此前，Brenipatide于2024年9月启动减重适应症的一期临床试 验。 值得一提的是，礼 ...

整理 | GLP1减重宝典内容团队 目前，尚无确凿证据显示GLP-1受体激动剂（GLP-1RA）药物与甲 研究的主要终点是评估从基线到研究结束的 HbA1c 水平变化，而次要终点包括体重变化。研究参与者还接受了基于问卷的治疗满意度评估。 口服司美格鲁肽 治疗患者的 HbA1c 水平从基线时的 8.6% 显著降低至研究结束时的 7.3%。 约有 8% 的研究对象在基线时 HbA1c 水平低于 7%。到研究结束时，48% 的参与 者的 HbA1c 水平低于 7%。 接受司美格鲁肽治疗后，体重显著减轻 5.8 公斤。 值得注意的是，口服司美格鲁肽治疗对糖化血红蛋白和体重的影响在接受糖尿病专家和非糖尿病专家治疗 的患者之间没有显著差异。 《糖尿病治疗》杂志最近发表的一项研究讨论了荷兰进行的 PIONEER REAL 研究的结果，该研究 评估了口服司美鲁肽在管理 2 型糖尿病和支持减肥方面的 功效。 口服司美格鲁肽为人们 选择减重药物 时提供更多方向。 ▍ 接受口服司美格鲁肽的患者，体重显著减轻 5.8 公斤，降糖效果显著，具有相当高的治疗满意度 2020年11月至2022年12月期间，PIONEER REAL 研究在 ...

Core Viewpoint - The article highlights a significant medical breakthrough with the FDA approval of the first innovative drug, Tzield (teplizumab), for delaying the onset of Type 1 Diabetes (T1DM), marking a new phase in diabetes treatment in China [4]. Group 1: Medical Breakthrough - The first prescriptions for Tzield were successfully issued at the Boao Future Hospital, indicating a milestone in diabetes management [4]. - The drug is designed to delay the onset of T1DM, providing hope for patients and families affected by this autoimmune disease [6]. Group 2: Early Screening and Monitoring - Early screening is crucial for high-risk individuals, particularly those with a family history of T1DM, as they are 15 times more likely to develop the disease compared to the general population [8]. - The latest guidelines recommend systematic screening for first-degree relatives of T1DM patients aged 1-45, emphasizing the importance of islet autoantibody (IAb) testing as a reliable predictive indicator [8][9]. - Regular blood glucose monitoring, including Oral Glucose Tolerance Test (OGTT), is essential for assessing glucose metabolism and disease progression [9]. Group 3: Intervention Strategies - The progression of T1DM can be delayed through timely interventions, with studies showing that 44% of stage 1 and 75% of stage 2 patients progress to stage 3 within five years [10]. - Establishing a structured follow-up system can significantly reduce the risk of diabetic ketoacidosis (DKA) by over 50% and extend the intervention window for high-risk groups [10]. - The use of CD3-targeted drug Tzield can preserve beta cell function and delay disease onset by nearly three years for stage 2 patients [10]. Group 4: Conclusion - A standardized early screening and dynamic monitoring system is essential for extending the intervention window for T1DM, ultimately improving long-term outcomes for patients [11].

对于准妈妈们来说，体重管理早已超越"美丑"的简单命题。这直接关系到母婴安全、分娩风险、产后恢复，甚至影响宝宝未来的代谢健 康——绝不只是"胖多胖少"的问题。 以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 2025年美国糖尿病协会(ADA)第85届科学年会上，一场关于孕期体重管理的学术交锋引发热议。来自美国母胎医学学会的Pa tri c k Ca t a l a n o博士与英国剑桥大学代谢研究专家Cl a ir e Me e k博士，分别代表两种观点：一方关注控重可能影响胎儿发育，另一方则强调科 学管理能实现母婴双重健康收益。这场辩论将重新定义我们对孕期体重管理的认知。 ▍孕期控重=影响胎儿发育？"谨慎派"专家发出警告 "怀孕不是一个人在吃，而是两个生命在成长。"Ca t a l a no博士在演讲中一针见血地指出。 他解释道，孕期增加的体重并非全是母体脂肪——约60%来自母体生理变化（如血容量增加、乳腺发育等），而40%则直接关联胎儿发 育（包括胎盘、羊水及胎儿本身）。 更重要的是，孕 ...

整理 | GLP1减重宝典内容团队 研究还提示了可及性差异：治疗组中白人比例高于对照组（71% vs 47%）。作者认为，结构性障碍可能不成比例地限制了黑人、拉丁 裔与亚裔患者的获得性，强调需要更公平的覆盖与外展。后续试验应优先提高样本多样性，以更好反映RA人群的真实构成。 胰高糖素样肽-1受体激动剂（GLP-1RA）主要用于治疗肥胖和2型糖尿病，但新的证据显示，它们或许也能帮助部分类风湿关节炎 （RA）患者。 一项发表在美国风湿病学会旗下期刊ACR Open Rheumatology的研究指出，在体重指数（BMI）≥27的RA患者中，GLP-1RA治疗可降 低疾病活动度并改善多项心血管风险指标。 由于超重与炎症及较差的RA结局密切相关，研究者评估了这类广泛使用的减重药物是否能在代谢效应之外，为超重或肥胖的RA患者带 来额外获益。 既往文献表明，合并肥胖的RA患者通常疾病活动更高、对标准治疗的反应更差。一项北美队列研究发现，超过三成RA患者同时符合肥 胖标准。从机制上看，脂肪组织通过过度分泌细胞因子与脂肪因子，诱发慢性促炎状态，加剧关节及全身炎症风险。 这种持续炎症可能加速RA进展并放大症状。肥胖本身也会损害 ...